桃红四物汤合六味地黄丸治疗糖尿病早期肾病微量白蛋白尿期的临床观察

Clinical Observation of Taohong Siwu Decoction Combined with Liuwei Dihuang Pills in Treating Early Diabetic Nephropathy with Microalbuminuria

摘要: 目的；客观评价桃红四物汤合六味地黄丸治疗早期糖尿病肾病的有效性及安全性。方法：将90例患者随机分为对照组(基础治疗 + 达格列净)与中药组(基础治疗 + 达格列净 + 中药汤剂(桃红四物汤合六味地黄丸)，比较两组治疗前后尿微量白蛋白与尿肌酐比值(UACR)、肝功能、血脂、电解质等指标及中医证候积分变化。结果：治疗后两组在尿微量白蛋白、血脂、血糖方面均有明显改善，与治疗前比较，差异均有统计学意义(P < 0.05)；并且中药组在降低UACR、低密度脂蛋白、血糖方面更优于对照组(P < 0.05)，同时中药组在改善患者症状上明显优于对照组(P < 0.05)，因此，在结合西药的治疗上，使用桃红四物汤合六味地黄丸治疗可减少患者尿蛋白，改善患者的临床症状，初步揭示中医药在短期内改善UACR和相关生化指标方面显示出潜力。

Abstract: To objectively evaluate the efficacy and safety of Taohong Siwu Decoction combined with Liuwei Dihuang Pills in treating early diabetic nephropathy. Methods: A total of 90 patients were randomly divided into a control group (basic treatment + dapagliflozin) and a TCM group (basic treatment + dapagliflozin + TCM decoction (Taohong Siwu Decoction combined with Liuwei Dihuang Pills)). The urinary albumin-to-creatinine ratio (UACR), liver function, blood lipids, electrolytes, and TCM syndrome scores were compared before and after treatment. Results: After treatment, both groups showed significant improvements in urinary microalbumin, blood lipids, and blood glucose compared to before treatment, with statistically significant differences (P < 0.05). Moreover, the TCM group outperformed the control group in reducing UACR, low-density lipoprotein, and blood glucose (P < 0.05). Additionally, the TCM group demonstrated significantly better symptom improvement than the control group (P < 0.05). Therefore, the combination of Taohong Siwu Decoction and Liuwei Dihuang Pills with Western medicine can reduce urinary protein and improve clinical symptoms, preliminarily revealing the unique advantages of TCM in delaying diabetic nephropathy.